Delving into the Latest Updates on Mesenchymal stem cell based exosome therapy (Cellular Biomedicine Group) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

MSCsExos (Cellular Biomedicine Group), hMSCExos (Cellular Biomedicine Group)

Target-

Mechanism-

Therapeutic Areas

Respiratory Diseases

Active Indication

Respiratory Distress Syndrome, Acute

Inactive Indication

Alzheimer DiseaseRespiratory Distress Syndrome, Adult

Originator Organization

AbelZeta Pharma, Inc.

Active Organization

AbelZeta Pharma, Inc.

Inactive Organization

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai Cellular Biopharmaceutical Group Ltd.

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

BACKGROUND3D-printing is widely used in regenerative medicine and is expected to achieve vaginal morphological restoration and true functional reconstruction. Mesenchymal stem cells-derived exosomes (MSCs-Exos) were applyed in the regeneration of various tissues. The current study aimed to explore the effctive of MSCs-Exos in vaginal reconstruction.METHODSIn this work, hydrogel was designed using decellularized extracellular matrix (dECM) and gelatin methacrylate (GelMA) and silk fibroin (SF). The biological scaffolds were constructed using desktop-stereolithography. The physicochemical properties of the hydrogels were evaluated; Some experiments have been conducted to evaluate exosomes' effect of promotion vaginal reconstruction and to explore the mechanism in this process.RESULTSIt was observed that the sustained release property of exosomes in the hydrogel both in vitro and in vitro.The results revealed that 3D scaffold encapsulating exosomes expressed significant effects on the vascularization and musule regeneration of the regenerative vagina tissue. Also, MSCs-Exos strongly promoted vascularization in the vaginal reconstruction of rats, which may through the PI3K/AKT signaling pathway.CONCLUSIONThe use of exosome-hydrogel composites improved the epithelial regeneration of vaginal tissue, increased angiogenesis, and promoted smooth muscle tissue regeneration. 3D-printed, lumenal scaffold encapsulating exosomes might be used as a cell-free alternative treatment strategy for vaginal reconstruction.

01 Aug 2024·Experimental Cell Research

Mesenchymal stem cells-derived exosomes alleviate senescence of retinal pigment epithelial cells by activating PI3K/AKT-Nrf2 signaling pathway in early diabetic retinopathy

Article

Author: Wang, Ying ; Bai, Lifang

Diabetic retinopathy (DR) is a major cause of vision loss and blindness in adults. Cellular senescence was involved in the pathogenesis of early-stage DR and is positively correlated with progression. Thus, our study aimed at exploring the effect and potential mechanism of Mesenchymal stem cells-derived exosomes (MSCs-EXOs) on Retinal Pigment Epithelial (RPE) cells senescence at an early stage of DR in vivo and in vitro. ARPE-19 cells were incubated in high glucose (HG) medium mixed with MSCs-EXOs to observe the changes in cell viability. Senescence-associated β-galactosidase (SA-β-gal) staining, Western blot and qRT-PCR were used to assess the expression of senescence-related genes and antioxidant mediators. Quantitative Real-Time polymerase chain reaction (qRT-PCR), Optical coherence tomography (OCT) Hematoxylin and eosin (HE) staining and Electroretinogram (ERG) were respectively used to verify cellular senescence, the structure and function of the retina. Our findings demonstrated that MSCs-EXOs inhibited HG-induced senescence in ARPE-19 cells. Furthermore, MSCs-EXOs reduced HG-induced cell apoptosis and oxidative stress levels while promoting cell proliferation. Mechanistically, HG suppressed PI3K/AKT phosphorylation as well as nuclear factor erythroid 2-related factor 2 (Nrf2) expression along with its downstream target gene expression in ARPE-19 cells. However, MSCs-EXOs reversed these changes by alleviating cellular senescence while enhancing antioxidant activity. In line with our results in vitro, MSCs-EXOs significantly ameliorated hyperglycemia-induced senescence in DR mice by downregulating mRNA expression of P53, P21, P16, and SASP. Additionally, MSCs-EXOs improved the functional and structural integrity of the retina in DR mice. Our study revealed the protective effect of MSCs-EXOs on cellular senescence, offering new insights for the treatment of DR.

01 Apr 2024·Bulletin of Experimental Biology and Medicine

Exosomes Derived from Mesenchymal Stem Cells: Therapeutic Opportunities for Spinal Cord Injury

Review

Author: Zhang, C

Spinal cord injury (SCI) is a serious neurological condition comprising primary and secondary injury and causing severe neurological impairments. The effect of the conventional treatment is limited, including supportive therapy and emergency surgery. Exosomes derived from mesenchymal stem cells (MSCs-Exos) were previously reported to exert its potential therapeutic effects on SCI. Compared with mesenchymal stem cells (MSCs) transplantation for SCI, MSC-Exos showed several superiorities. In the present review, we summarized the revealed data of mechanisms underlying MSC-Exos repairing of SCI and discussed the issues of MSC-Exos use. Thus, in this review we summarized the latest studies on MSCs-Exos in the therapy of SCI and discussed whether MSCs-Exos can be applied to SCI and the prospects of transformation application.

100 Deals associated with Mesenchymal stem cell based exosome therapy (Cellular Biomedicine Group)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Respiratory Distress Syndrome, Acute	Phase 2	CN	AbelZeta Pharma, Inc.	30 Nov 2020
Respiratory Distress Syndrome, Adult	Phase 2	CN	Ruijin Hospital, Shanghai Jiaotong University School of Medicine	16 Aug 2020
Respiratory Distress Syndrome, Adult	Phase 2	CN	Shanghai Cellular Biopharmaceutical Group Ltd.	16 Aug 2020
Alzheimer Disease	Phase 2	CN	AbelZeta Pharma, Inc.	01 Jul 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04313647 (CTgov)	Phase 1	-	24	1X level of MSCs-Exo (1X Level)	ylyrpyiezv(zyfvmjdnkj) = lsvbnqcoiz zhiatsgnxp (klkashzgpc, pxkpkhgqhe - xfcemgnxsd) View more	-	04 Aug 2021
				2X level of MSCs-Exo (2X Level)	ylyrpyiezv(zyfvmjdnkj) = yvavewsmnb zhiatsgnxp (klkashzgpc, hyhwjirkwp - gvkfvwrxtt) View more